This activity was originally presented at the 2026 Oncology Pharmacists Connect Conference.
Program Description
Non–small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, with ROS1 rearrangements identifying a small but critical subset of patients. These patients are often younger and non-smokers and face a high risk of central nervous system (CNS) involvement. While the therapeutic landscape has expanded to include multiple generations of tyrosine kinase inhibitors (TKIs), the emergence of complex resistance mechanisms poses a significant challenge to long-term disease control. This session is designed to equip oncology pharmacists with the advanced clinical and operational expertise required to navigate the evolving treatment landscape in ROS1-rearranged NSCLC. Because ROS1 fusions are often mutually exclusive with other oncogenic drivers, comprehensive biomarker testing via next-generation sequencing (NGS) has become an important first step to ensure these alterations are addressed through appropriate treatment selection and prevents the use of less effective, non-targeted therapies. Oncology pharmacists will explore the mechanistic differentiation of first- and next-generation TKI agents while exploring the clinical implications of investigational therapies. By synthesizing evidence from pivotal trials, this session provides a framework for interpreting NGS sequencing data, selecting initial therapy based on CNS burden, and strategically sequencing agents upon progression. Speakers will emphasize the pharmacist’s role in institutional leadership from embedding retesting triggers into workflows to proactively managing unique toxicity profiles to optimize patient adherence and outcomes.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: June 30, 2026
Expiration date: June 30, 2027
Learner level: Intermediate, Advanced
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Use molecular and resistance testing results to guide evidence-based ROS1-directed treatment planning across lines of therapy in non-small cell lung cancer
- Apply clinical trial data, central nervous system activity, and resistance mutation profiles for selection and sequencing of ROS1-targeted therapies
- Construct mechanism-based toxicity monitoring and management plans for ROS1-targeted therapies that support adherence and optimize long-term outcomes
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
